NYON, Switzerland, Dec. 9, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTCBB:MYMX), announced today that it has retained Lazard as its financial advisor to provide the company with independent advice on strategic transactions, tactical acquisitions and other financial matters for the period 2009 to 2011.
"With the unfailing support of a small group of Swiss investors, we have raised CHF 32 million over the last 3 years, and thanks to those investors we have been able to achieve decisive breakthroughs in the development of a preventative vaccine for HIV/AIDS. Not wishing to remain a single product company, we acquired a Malaria vaccine using the same delivery system (virosome) as our HIV/AIDS vaccine," stated Christian J. F. Rochet, President and CEO of Mymetics, who added, "the advice and the support of Lazard will enable us to achieve the second phase of our development, which will be primarily reflected in 2009 through strategic acquisitions and partnerships."
About Lazard
Lazard, one of the world's preeminent financial advisory and asset management firms, operates from 41 cities across 24 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating back to 1848, the firm provides advice on mergers and acquisitions, restructuring and capital raising, as well as asset management services to corporations, partnerships, institutions, governments, and individuals.
About Mymetics Corporation
Mymetics' corporate objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including HIV/AIDS and Malaria. In Q4 2008 Mymetics will commence Phase 1b Human Clinical trials of their HIV/AIDS preventative vaccine candidate which showed extremely promising results (see Press Release September 16, 2008) as well as continuing Mymetics' long term Malaria vaccine in Phase II Human Clinical trials. Additional applications of Mymetics' research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation. Long range growth plans key to Mymetics' development include acquisitions of prophylactic or therapeutic vaccines against breast cancer, candidiasis, RSV, malaria and hepatitis.
The Mymetics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5478